Zoran Gatalica
University of Oklahoma
340 Papers
2.1K Citations
Zoran Gatalica is an academic researcher from University of Oklahoma. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 55, co-authored 323 publications. Previous affiliations of Zoran Gatalica include University of New South Wales & Creighton University Medical Center.
Chat about Author
Papers
Molecular variances between rectal and left-sided colon cancers.
John L. Marshall,Heinz-Josef Lenz,Joanne Xiu,Wafik S. El-Deiry,Jeffrey Swensen,Hesham El Ghazaly,Zoran Gatalica,Jimmy J. Hwang,Philip A. Philip,Anthony F. Shields,Mohamed E. Salem +10 more
TL;DR: It is shown that left sided colon tumors (LT) respond differently to biologics compared with right-sided tumors, likely due to molecular differences, and molecular variations between LT and rectal tumors remain undefined.
12
RNA-Seq analysis of glioma tumors to reveal targetable gene fusions.
Deepa S. Subramaniam,Joanne Xiu,Shwetal Mehta,Zoran Gatalica,Jeffrey Swensen,Nader Sanai,Amy B. Heimberger +6 more
TL;DR: RNA-sequencing is used to interrogate a large cohort of gliomas for targetable genetic fusions and found the most frequent fusions seen involved FGFR...
11
Barrett’s esophagus in the patients with familial adenomatous polyposis
TL;DR: Both classic FAP and attenuated FAP phenotypes were associated with BE and patients with FAP appear to have increased risk for the development of BE, which on average develops some 20 years earlier than in patients without FAP.
11
Breast carcinoma with neuroendocrine features: a brief review.
Petra Jurčić,Božo Krušlin,Zoran Gatalica,Sanati Souzan,Semir Vranic +4 more
- 24 Dec 2017
TL;DR: Therapeutic options in the metastatic setting include surgery, chemotherapy, peptide receptor radionuclide therapy and molecular-targeted agents, which are not mutually exclusive and are interchangeable.
11
Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group
TL;DR: Tumor-type agnostic drug therapies work across cancer types and present a significant novel shift in precision cancer medicine as discussed by the authors , which is the consequence of carefully designed clinical trials that showed the value of tumor biomarkers, not just in diagnosis but in therapy guidance.